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ABSTRACT 
 
Objective: The objective of this selective EBM review is to determine whether or not oral 
vitamin D supplementation is safe and effective for adults as therapy to improve symptoms 
associated with seasonal affective disorder (SAD) during wintertime. 
 
Study Design: This review is based on three randomized controlled trials (RCTs) which were 
published in 2006, 2012, 2014. Two of the studies were double blind and placebo controlled. The 
studies evaluated the efficacy of oral vitamin D supplementation for improvement of seasonal 
affective disorder (SAD) symptoms. One of the studies also evaluated safety. 
 
Data Sources: All articles used were published in English, in peer-reviewed journals and found 
in PubMed during the time period of November 2015 to February 2016. 
 
Outcomes Measured: The outcomes measured were symptoms associated with SAD. One study 
measured subjective psychological well-being qualities (energy and vitality, social functioning, 
role functioning, and mental health), which were measured by Mean Component Score (MCS). 
The other two studies evaluated symptoms associated with SAD and perceived change from 
normal in: length of sleep, social activities, mood, weight, appetite, energy level by using 
Structured Interview Guide for the Hamilton Depression Rating Scale – Seasonal Affective 
Disorders (SIGH-SAD) and Global Seasonality Score (GSS) tools. 
 
Results: None of the studies evaluated in this review had results to suggest that vitamin D 
supplementation is effective for improving symptoms associated with SAD. Dumville (2006) 
found no significant evidence (p = 0.262). Frandsen (2014) and Kjaergaard et al. (2012) both 
found no significant difference between placebo and vitamin D with p values of 0.7 and 0.734 
respectively. Kjaergaard et al. (2012) also found there to be no significant difference in adverse 
events between the placebo and vitamin D groups. 
 
Conclusions: This review suggests that although oral vitamin D supplementation is safe, it is not 
effective for adults as therapy to improve symptoms associated with SAD during wintertime. 
 
Keywords: vitamin D, seasonal depression, adults 
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Introduction 
 
Seasonal Affective Disorder (SAD) is a seasonal pattern of depression with onset and 
remission at predictable times of year.1 The hallmark symptoms include: fatigue, weight gain, 
lack of energy, hypersomnia, and episodic carbohydrate craving.1 It is more common in women 
and at higher latitudes.1 Most people with SAD experience symptoms that start in the fall and 
continue into winter.2 The mainstay of treatment for SAD at this time includes light therapy, 
psychotherapy, and medications.2 This paper evaluates three randomized controlled trials, two of 
which were double blind placebo controlled, investigating whether vitamin D supplementation is 
safe and effective as treatment for SAD symptoms. 
While not as prevalent as major depressive disorder, SAD is still common. In 2009-2010 
there were approximately eight million ambulatory visits for depression including those with 
SAD.3 About 5% of the US population experiences SAD in a given year with symptoms lasting 
approximately 40% of the year.4 Symptoms of SAD can be severe and may cause significant 
impairment of a person’s ability to function normally at work, school, or home.4 Furthermore, it 
is a condition that is frequently encountered in primary care and may be easily overlooked or 
downplayed as simply being “under the weather”. According to the medical resource UpToDate, 
SAD affects 5-10% of primary care patients and 15% of depressed patients.5 This represents a 
significant demand of time by clinicians and money on the healthcare system as a whole. The 
economic burden of treating SAD in particular is not known, however, when it is considered 
together with the cost of treating major depression in the United States it was estimated to be a 
staggering $210.5 billion in 2010 and has been increasing.6  
As one might expect, depression has been shown to negatively affect patients’ social 
relationships and performance at work or school.7 In this way, if depression or SAD is left 
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untreated then it may have a significantly negative impact on patients’ overall wellness. Not only 
does depression affect self-reported metrics of wellness and quality of life, but it has also been 
shown to negatively influence objective measures of health status.8 One of the ways that 
depression, and presumably mental illness in general, may affect one’s health or wellness status 
is through noncompliance. Depressed patients are three times more likely to be noncompliant 
with medical treatment recommendations.9 Clinicians need to be vigilant in recognizing and 
treating depression symptoms if they are to truly provide high quality medical care. 
The underlying pathophysiology and etiology of SAD and depression is unknown, 
however, it is believed that several different biological, psychological, and environmental 
mechanisms are involved.10 A large portion of these mechanisms reflect neuroendocrine 
abnormalities. These include: increased cortisol and corticotropin releasing hormone, increase in 
adrenal size, decreased inhibitory response of glucocorticoids to dexamethasone, a blunted 
response of thyroid stimulating hormone to thyroid releasing hormone, and an increase in 
inflammatory cytokines.1 From a biological perspective, it has been demonstrated that diurnal 
variations in symptoms correlate with changes in circadian rhythm and neurotransmitters, which 
suggests that a dysregulation of biologic rhythms may also play a role.1 SAD in particular is 
thought to be associated with reduced levels of sunlight in fall and winter, thereby causing 
disruptions in circadian rhythm, levels of serotonin and melatonin, and manifesting as alterations 
in mood and symptoms of depression.11 
At this time, the first line treatments for SAD include light therapy of two hours at 2500 
lux or 30 minutes at 10,000 lux every day, or antidepressant medication (SSRIs) like fluoxetine 
10 mg every day.12 Light therapy has been shown to be effective, however, not without a few 
drawbacks. Compliance and consistency are crucial to achieve the full benefit of therapy, and 
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due to the possible side effects like headache, eye strain, and agitation, it is recommended that it 
only be used under the supervision of a mental health professional.7 For many patients, the time 
and schedule commitment as well as the associated monetary cost to the patient of frequent 
office visits may prove to be impractical. Vitamin D has been hypothesized as a potential 
treatment option for SAD because of research that has implicated its role in depression, low cost, 
and the convenience of oral supplementation.13 Vitamin D, or more specifically cholecalciferol 
(D3), is a neurosteroid hormone that is involved with many brain processes such as 
neuroimmunomodulation, neuroprotection, neuroplasticity, and brain development.13 Low levels 
of vitamin D are associated with depression and also prevalent during the winter months, making 
it a prime candidate to pursue as a therapy option for SAD symptoms. 
Objective 
 
The objective of this selective EBM review is to determine whether or not oral vitamin D 
supplementation is safe and effective for adults as therapy to improve symptoms associated with 
seasonal affective disorder (SAD) during wintertime. 
Methods 
 
 This review evaluates three randomized controlled trials, two of which were double blind 
and placebo controlled. Studies were selected based on their relevance to this review’s objective 
and according to specific criteria including: the target population, types of interventions used, 
comparisons made, and the outcomes measured. All three of the studies included the target 
population of adults over 18 years old, in some form. Dumville14 studied women over 69 years, 
Frandsen15 studied adults ages 18-65 years old, and Kjaergaard et al.16 studied adults ages 30-65 
years old. 
 All of the studies used oral vitamin D supplementation as their intervention. Dumville 
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used Calcichew D3 forte tablets - two tablets per day were taken orally providing a daily total of 
1000mg calcium and 800IU vitamin D for 6 months from November to April.14 Frandsen used a 
daily dose of 70 μg vitamin D x 12 weeks.15 Kjaergaard et al. used vitamin D3 capsules (20,000 
IU cholecalciferol) x 2 per week x 6 months.16 Two of the studies compared the intervention 
groups versus placebo control groups and one study compared the intervention group versus a no 
intervention group. The outcomes that were measured in all of the studies were symptoms 
associated with SAD such as changes in mental well-being, social activity, mood, appetite, and 
energy level. The ways in which the outcomes were measured differed from study to study and 
the details are described in the Outcomes Measured section of this review. 
The author performed searches for the articles in PubMed during the time period from 
11/23/15 to 2/26/16. The articles were found using the following key words in search queries: 
vitamin d, seasonal depression, and adults. All of the articles were published in English and 
collected from peer reviewed journals. The articles were selected based on their relevance to this 
review’s clinical question and whether or not they included the target patient oriented outcomes 
(POEM). Inclusion and exclusion criteria were also used in order to focus the article selection 
process. The inclusion criteria were simply that each article had to be a randomized controlled 
trial. If the article included patients under the age of 18 years old, then it was excluded from 
consideration for this review. The inclusion and exclusion criteria that were employed in each 
specific study are included in Table 1 below. Many different statistics were reported or used in 
the selected articles including: difference of mean change from baseline, p value, confidence 
interval (CI), mean change from baseline, median, range, delta, and numbers needed to harm 
(NNH). A p value was provided in all of the studies, while a NNH value was only provided in 
Kjaergaard et al.16 See Table 1 below for the demographics and characteristics of the included 
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studies. 
Table 1: Demographics and Characteristics of Included Studies 
 
Study Type # 
Pts 
Age 
(yrs) 
Inclusion 
Criteria 
Exclusion Criteria W/D Interventions 
Dumville14 
(2006) 
RCT 2117 > 70 Women ≥70 
years old, 
took < 500 
mg of 
supplemental 
Ca daily, did 
not have 
bladder or 
kidney 
stones and 
had one or 
more risk 
factors 
A life expectancy of 
<six months, or if 
they had cognitive 
impairments 
496 Calcichew D3 
forte tablets - 2 
tablets PO QD 
providing a 
daily total of 
1000mg 
calcium and 
800IU vitamin 
D for 6 months 
from 
November to 
April. 
 
Frandsen15 
(2014) 
Double 
blind 
RCT 
50 18-
65 
Healthcare 
worker in the 
region of 
Southern 
Denmark, 
18– 65 years 
old, and had 
moderate 
symptoms 
associated 
with SAD 
Any form of 
schizophrenia, 
bipolar affective 
disorder, sarcoidosis, 
tuberculosis and 
pregnancy, or an 
intake of more than 
10 μg vitamin D per 
day. Serum lab value 
criteria for Vit D, Ca, 
PO, and PTH were 
also used 
14 Daily dose of 
70 μg vitamin 
D x 12 weeks 
 
Kjaergaard 
et al.16 
(2012) 
Double 
blind 
RCT 
237 30-
75 
Serum 
25(OH)D 
levels found 
to be below 
the 20th 
percentile in 
the sixth 
Tromso 
study 
conducted 
between 
2007 and 
2008. 
 
Patients with 
comorbidities, fertile 
women not using 
contraception, taking 
vitamin D 
supplements or mood 
altering medication, 
possible 
hyperparathyroidism, 
or severe depression 
7 Vitamin D3 
capsules 
(20,000 IU 
cholecalciferol) 
x 2 per week x 
6 months 
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Outcomes Measured 
 
Dumville measured symptoms of SAD by using a Mental Component Score (MCS) tool 
which was used to assess participants’ self-reported psychological well-being at baseline 
(November) and at six months (April).14 This score was based on four categories of a more 
comprehensive health related quality of life questionnaire known as the SF-12. The four 
categories considered were: energy and vitality, social functioning, role functioning (emotional), 
and mental health. 
Frandsen measured symptoms of SAD as a recorded score from the self-reported 
questionnaire Structured Interview Guide for the Hamilton Depression Rating Scale – Seasonal 
Affective Disorders (SIGH – SAD).15 The SIGH-SAD is a 24 item scripted version of the 
Hamilton Depression Rating Scale that was modified to better reflect the characteristic 
symptomatology of SAD. Assessments were performed at baseline (January) and at 12 weeks 
(March) later. 
Kjaergaard et al. studied the perceived change from normal in six categories of symptoms 
related to SAD: length of sleep, social activities, mood, weight, appetite, and energy level.16 This 
was performed by using Global Seasonality Score (GSS) - a sum total score based on responses 
from the Seasonal Pattern Assessment Scale (SPAQ) questionnaire. In the SPAQ, participants 
rated the change that they experienced in each of the six categories from 0 to 4, with a 0 
indicating no change and a 4 indicating a great change. Assessments were performed at baseline 
(October) and after six months (April). 
Results 
 
 In the Dumville RCT, a total of 2117 women were recruited to the trial from primary care 
in three areas of the UK.14 This was done according to the inclusion and exclusion criteria 
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previously described in Table 1. 9% of the subjects were smokers. The target population was 
chosen based on the hypothesis that SAD is linked to vitamin D deficiency; a common problem 
among the elderly and during the winter months. Two groups were assigned randomly - a control 
group made of 1205 women and an intervention group made of 912 women. The intervention 
group was given calcium and vitamin D supplementation (detailed in the Methods section) while 
the control group did not. Adherence to treatment was not explicitly mentioned. Baseline 
measures were taken between the months of May and October according to the methods 
described in the Outcomes Measured section. Of these women, only 1621 (77%) had an SF-12 
score deemed to be valid (more than 5 items completed) both at baseline and six months and 
were considered for further analysis through Mental Component Scoring (MCS). Results were 
analyzed using SPSS 11, all analysis was done on an intention to treat basis, and the relationship 
between vitamin D supplementation and six month MCS score was assessed using ANCOVA 
adjusting for score at baseline and age. A summary of results can be seen in Table 2. 
Table 2 – Difference in mean MCS scores for control and treatment groups at 6 months 
Difference between control and treatment six month 
scores after controlling for baseline score and age 
P value Confidence Interval (CI) 
-0.49 0.262 (-1.34 – 0.81) 
 
This study demonstrates that after six months of intervention with 800 IU of vitamin D 
supplementation daily, the intervention group of elderly women experienced no significant 
improvement in their Mental Component Score, a reflection of their mental health and symptoms 
associated with SAD. The p value of 0.262 is well out of the statistically significant threshold of 
<0.05, making these results not significant. 
 In the Frandsen double-blind, placebo controlled, RCT, 3345 healthcare professionals 
from hospitals in Southern Denmark were invited to participate.15 50 participants were screened 
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by a research nurse. Seven were excluded before randomization according to the inclusion and 
exclusion criteria described in Table 1, and of the remaining 43 included in the trial, only 34 
were eventually able to complete the entire study. The main inclusion criteria were adults age 18-
65 with the presence of moderate SAD symptoms as determined by a score of 8 points or more 
on question 2 of the Seasonal Pattern Assessment Questionnaire, Seasonal Affective Disorders 
(SPAQ-SAD). Participants were randomized to a treatment group (22 people) which received 70 
micrograms of vitamin D daily or a controlled group (21 people) that received placebo daily for a 
period of 12 weeks during the winter period. The primary outcome that was assessed was the 
sum of the self-reported SIGH-SAD. This assessment was performed at baseline and at 12 weeks 
after baseline. Known side effects of vitamin D supplementation including: fatigue, muscle 
spasm, pain, nausea, constipation, as well as severe/adverse events were also recorded at baseline 
and 12 weeks. Treatment adherence was accounted for by counting the returned pills after 12 
weeks. The analyses were conducted on an intention to treat basis. All of the subjects who 
entered into the trial were accounted for at the conclusion, however, 23% were lost to follow up. 
A summary of results is included below in Table 3. 
Table 3 – Mean change from baseline after 12 weeks for treatment and control groups 
 Mean change from baseline Standard Deviation 
Treatment Group -6.4 7.3 
Control Group -6.8 9.5 
 
The p value of the primary outcome was not significant at 0.7 and the confidence interval 
was -3.27 to 4.81. Additionally, there were no significant differences between treatment and 
control groups at baseline. There was significant improvement of SIGH-SAD scores for all 
participants from baseline to the conclusion of the study. All analyses were completed using 
STATA/IC 11 software. Treatment adherence was high at 85.9%. There were no significant 
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differences between groups for known side effects or adverse events from vitamin D 
supplementation. 
 In the Kjaergaard et al. double-blind, placebo controlled, RCT, a nested case control 
study was performed evaluating adults 30-75 years old for serum vitamin D levels in Tromso, 
Norway.16 Individuals with low levels, according the inclusion and exclusion criteria described 
in Table 1, were then invited to participate in an interventional study whereby 243 participants 
were randomized to a control and treatment group. A total of 230 participants actually completed 
the study. The treatment adherence rate was 94%. At baseline there were no differences among 
control and treatment groups. Treatment group received vitamin D3 capsules (20,000 IU 
cholecalciferol) x 2 per week x 6 months, and the control group received placebo x 2 per week x 
6 months. Assessment for outcomes was done at baseline (October 2009) and after six months 
(April 2010). Data was analyzed using a per protocol approach and an intention to treat 
approach. Subjects lost to follow up were analyzed by using a last observation carried forward 
method thus giving participants who did not complete the study a change in depression score of 
zero. Statistical analyses were performed using PASW. Four primary outcomes were measured, 
of which only the self-reported Global Seasonality Score (GSS) was considered for this review. 
Respiratory harm from intervention was also reported. A summary of results can be viewed in 
Table 4. 
Table 4 – Change in median GSS at 6 months minus score at baseline (delta) 
 Delta Range 
Treatment group -0.72 3.4 
Control group -0.28 4.66 
 
The p value for delta was found to be non-significant at 0.734. There was also no 
significant difference in adverse events between the treatment and control groups. Table 5 below 
shows data for respiratory adverse events during the 6-month intervention period, which was the 
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most common adverse event detected in both control and treatment groups overall. Table 6 
below shows the calculated measures of harm from placebo versus vitamin D treatment groups 
for respiratory adverse events. 
Table 5 – Respiratory adverse events during the intervention period between groups 
 Placebo (n=121) Vitamin D (n=122) 
Respiratory 61 67 
 
Table 6 – Calculated measures of harm for respiratory adverse events 
Control event 
rate (CER) 
Experimental 
event rate (EER) 
Relative risk 
increase (RRI) 
Absolute risk 
increase (ARI) 
Number needed 
to harm (NNH) 
50.4% 54.9% 8.93% 4.5% 23 
 
 The Kjaergaard et al. trial was the only one of the studies chosen for this review that 
evaluated safety and adverse events from the intervention of vitamin D supplementation. The 
CER and EER show that roughly 50 – 55% of the patients in the treatment and control groups 
experienced adverse respiratory events during the trial, and at equal proportions. The NNH of 23 
indicates that for every patient given vitamin D supplementation, one will likely have an adverse 
respiratory event when compared to the control. 
Discussion 
 
While the overwhelming results of the three studies used in this review do not provide 
any significant evidence to suggest that vitamin D is an effective therapy for improving 
symptoms of SAD, each study had specific limitations which may have affected their results. 
Dumville used a population at risk for SAD – elderly women, with low vitamin D levels, living 
at a high latitude during the winter – but the actual presence of SAD in the trial population was 
never measured.14 The treatment and control groups did however have similar SF-12 scores at 
baseline. Dumville also admits that in their study they did not see the expected seasonal decline 
in mental health scores that would be expected if a large proportion of their subjects actually had 
SAD.14 Furthermore, the study population of elderly women are indeed adults eligible for this 
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review but their reflection of adults in general is limited. Frandsen admits that their treatment 
effect could have been diminished by not including low vitamin D patients at baseline (higher 
risk for SAD) or requiring patients to have a higher SAD severity for inclusion.15 Also, their 
sample size was small and the study could have been subject to type II error. The main limitation 
of the Kjaergaard et al. study was similar to Dumville in that they used a target population at risk 
of SAD without actually confirming the presence of it before intervention.16 It is also plausible 
that six months is not long enough of a time frame to properly evaluate SAD, or that the vitamin 
D supplementation was at too high of a dose.16 
Conclusion 
 
None of the studies selected for this review provided any significant evidence that oral 
vitamin D supplementation is an effective means of improving or preventing symptoms 
associated with SAD in adults during wintertime. In Kjaergaard et al., they were able to show 
that patients with low vitamin D levels have higher depression scores, but they were not able to 
demonstrate that vitamin D supplementation conferred any improvement.16 They propose that 
this may be due to the possibility that low vitamin D levels are a result of depression symptoms 
rather than a cause for it.16 In regards to the safety of vitamin D supplementation, this review 
concludes that it is indeed safe based on the results of Kjaergaard et al. when used for treatment 
of depression or SAD symptoms and that the risk of adverse events is low. 
Further studies are warranted to explore the relationships between vitamin D levels, brain 
function, and mental health. Future design methods may be improved by: confirming the 
presence of SAD symptoms at baseline prior to intervention, using a questionnaire tailored 
specifically for SAD, and using multiple treatment groups to cover a wide range of vitamin D 
supplementation dosages.
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